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Abstract
Small-quantity lipid-based nutrient supplements (SQ-LNS) are promising home fortification
products, but the optimal zinc level needed to improve growth and reduce morbidity is uncer-
tain. We aimed to assess the impact of providing SQ-LNSwith varied amounts of zinc, along
with illness treatment, on zinc-related outcomes compared with standard care. In a placebo-
controlled, cluster-randomized trial, 34 communities were stratified to intervention (IC) or non-
intervention cohorts (NIC). 2435 eligible IC children were randomly assigned to one of four
groups:1) SQ-LNS without zinc, placebo tablet; 2) SQ-LNS containing 5mg zinc, placebo tab-
let; 3) SQ-LNS containing 10mg zinc, placebo tablet; or 4) SQ-LNSwithout zinc and 5mg zinc
tablet from 9–18months of age. During weekly morbidity surveillance, oral rehydration salts
were provided for reported diarrhea and antimalarial therapy for confirmed malaria. Children
in NIC (n = 785) did not receive SQ-LNS, tablets, illness surveillance or treatment. At 9 and
18months, length, weight and hemoglobin were measured in all children. Reported adher-
ence was 97±6% for SQ-LNS and tablets. Mean baseline hemoglobin was 89±15g/L. At 18
months, change in hemoglobin was greater in IC than NIC (+8 vs -1g/L, p<0.0001), but
79.1% of IC were still anemic (vs. 91.1% in NIC). Final plasma zinc concentration did not differ
by group. During the 9-month observation period, the incidence of diarrhea was 1.10±1.03
and of malaria 0.54±0.50 episodes per 100 child-days, and did not differ by group. Length at
18 months was significantly greater in IC compared to NIC (77.7±3.0 vs. 76.9±3.4cm;
p<0.001) and stunting prevalence was significantly lower in IC (29.3%) than NIC (39.3%;
p<0.0001), but did not differ by intervention group within IC. Wasting prevalence was also
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significantly lower in IC (8.7%) than in NIC (13.5%; p = 0.0003). Providing SQ-LNS daily with
or without zinc, along with malaria and diarrhea treatment, significantly increased growth and
reduced stunting, wasting and anemia prevalence in young children.
Trial Registration
ClinicalTrials.gov NCT00944281
Introduction
Growth stunting in early life continues to be a critical public health concern in low-income
countries [1,2]. Diarrhea and pneumonia are leading causes of morbidity and mortality among
young children in low income countries and the case fatality for these illnesses is increased in
undernourished children [3,4]. Although the global malaria burden has decreased in the past
decade, it remains very high in sub-Saharan Africa [5]. Supplemental zinc increases linear
growth and weight gain and reduces the incidence of diarrhea and pneumonia among children
under 5 years of age [6–10]. Small quantity lipid-based nutrient supplements (SQ-LNS) have
been designed to prevent undernutrition and promote health and development [11]. SQ-LNS
provide ~20 g or ~110–120 kcal per day along with additional protein, essential fatty acids and
22 micronutrients, including zinc. Trials investigating the potential of SQ-LNS and medium-
quantity LNS (MQ-LNS; at ~50 g or ~250–280 kcal per day) to prevent malnutrition and pro-
mote growth have yielded mixed results [12–17]. Only a few of these studies reported morbidi-
ty outcomes, and none detected any benefit of SQ-LNS [14,15]. Thus, the beneficial impact of
zinc on growth and morbidity is less clear when provided mixed with food, such as point-of-
use fortification of complementary foods with SQ-LNS or multiple micronutrient powders
(MNP), possibly because of insufficient zinc content.
While there is strong evidence that providing 3–20 mg zinc supplements daily as syrup or
tablets consistently results in significantly increased plasma zinc concentrations (pZn) in the
zinc supplemented group compared to the placebo control group [18], findings from home for-
tification trials are inconsistent. Most, but not all, studies providing 5 mg zinc in a daily dose of
SQ-LNS or MNP did not find increased pZn at the end of the study [19–21]. One study in
young Iranian children who received 5 mg of zinc in MNP and one study in young Cambodian
children who received 10 mg of zinc in MNP found a significantly increased pZn at the end of
the study compared to a placebo control group and non-intervention group, respectively
[22,23]. Possible explanations for this lack of response in biochemical and functional outcomes
are: 1) the dose of zinc was inadequate because less zinc is absorbed from zinc-containing prep-
arations that are provided with meals than from water-soluble zinc supplements provided be-
tween meals, 2) the study populations were not zinc deficient, so they did not respond
functionally to additional zinc, and/or 3) zinc consumed with meals was taken up preferentially
by non-metabolically active zinc pools.
The present study had two primary objectives: 1) To compare zinc-related functional re-
sponses among young Burkinabe children who received SQ-LNS containing 0, 5 or 10 mg of
zinc and placebo tablet or SQ-LNS without added zinc, plus 5 mg zinc tablets along with treat-
ment for diarrhea and malaria episodes; and 2) to compare the impact of the intervention pack-
age among children in intervention vs. non-intervention communities. Cluster-randomization
at the level of the family compound (i.e. concession) in the intervention communities was used
to prevent cross-contamination between intervention groups through food sharing. Major
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outcomes included physical growth, morbidity from common infections (specifically, diarrhea
and malaria), and change in pZn.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol.
Study Design and Participants
The study was designed as a partially masked, placebo-controlled, cluster-randomized inter-
vention trial. The trial was conducted from April 2010 to July 2012 in rural communities of the
Dandé Health District in southwestern Burkina Faso. Ethical approval for the study protocol
and the consent procedure was provided by the Institutional Review Boards of the Centre
Muraz in Bobo-Dioulasso (Burkina Faso) and the University of California Davis (USA). The
study was registered as a clinical trial with the U.S. National Institutes of Health (www.
ClinicalTrials.gov; NCT00944281).
Nine-month old infants were identified by periodic censuses in the study area. Written, in-
formed consent was obtained from one of the child’s primary caregivers (mother, father or
legal guardian). In case the caregiver was illiterate, an impartial witness was present during the
consent process, who confirmed that the information in the consent document was accurately
explained to the participant, and that consent was freely given. Children were considered eligi-
ble if they were 8.8 to 9.9 months of age, resided permanently in the area, planned to be avail-
able during the study period and had written parental consent. Exclusion criteria were:
hemoglobin (Hb)<50 g/L, weight-for-length<70% of the median of the National Center for
Health Statistics/World Health Organization (NCHS/WHO) growth reference [24] presence of
bipedal edema, other severe illness warranting hospital referral, congenital abnormalities po-
tentially interfering with growth, chronic medical conditions requiring frequent medical atten-
tion, known HIV infection of infant or mother, history of allergy towards peanuts, history of
anaphylaxis or serious allergic reaction to any substance requiring emergency medical care,
and concurrent participation in any other clinical trial. Once enrolled, children were with-
drawn from study participation when absent from the study for more than 3 weeks, although
data collected until that time were retained.
Sample Size
The sample size estimates were based on the number of children needed in each group to detect
(with a significance level of P<0.05 and power>0.80) effect sizes that are consistent with the
magnitude of effects observed in previous zinc supplementation trials [6,25]. In particular, the
sample sizes were based on an effect size of>0.22 for diarrhea incidence, malaria incidence,
and physical growth; and 0.6 for change in pZn. The target sample size per intervention group
for incidence of diarrhea and malaria and growth was n = 583 and for biochemical indicators
of nutritional status n = 85. This included an assumed attrition rate of 15% for morbidity and
growth outcomes and 20% for the biochemical outcomes. The estimated sample size for the
NIC was increased for an assumed design effect of 1.5 due to the cluster sampling design.
Randomization and Masking
This trial included two levels of randomization: 1) the community and 2) the concession. Thir-
ty-four communities that were accessible year-round were chosen. A statistician at the Univer-
sity of California Davis stratified individual communities by selected indicators (population
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size; proximity to road and Bobo-Dioulasso; and health clinic affiliation) and computer-gener-
ated an assignment within strata to participate in the intervention cohort (IC; 25 communities)
or in the non-intervention cohort (NIC; 9 communities). The same statistician, who was
blinded to the intervention, generated a random allocation sequence at the level of the conces-
sion for the enrollment of eligible infants in the IC. Eligible children meeting the inclusion cri-
teria were allocated to one of four interventions from 9 to 18 months of age: 1) SQ-LNS
without zinc, and placebo tablet (LNS-Zn0), 2) SQ-LNS with 5 mg zinc, and placebo tablet
(LNS-Zn5), 3) SQ-LNS with 10 mg zinc, and placebo tablet (LNS-Zn10), or 4) SQ-LNS without
zinc, and 5 mg zinc tablet (LNS-TabZn5). Children in the intervention groups received free
treatment for diarrhea, malaria and fever, as described in more detail below. Children in the
NIC did not receive SQ-LNS or tablets from 9 to 18 months of age, nor any illness treatment,
but received SQ-LNS from 18 to 27 months after the data collection was finished. The trial was
partially masked, as all participants, field staff and researchers remained blinded to the four in-
tervention groups until data analyses were completed, but were aware which communities
were assigned to IC and NIC.
The LNS products were developed for the iLiNS project [11] by Nutriset SAS (Malaunay,
France) and tested for acceptability [26]. A weekly ration of LNS was initially delivered to par-
ticipating children in plastic cups containing 140 g (sufficient for one week) and later in seven
sachets containing 20 g each. The child’s caregiver was advised to feed the day’s allotment
(20 g = 2 spoonsful) mixed in food during two separate meal times. The LNS for each treatment
group were identical, except for their zinc content. Besides zinc, a daily ration of LNS provided
118 kcal and 6 mg iron along with 20 other micronutrients [11]. Table 1 shows the nutrient
content of a daily ration of SQ-LNS compared with the Recommended Nutrient Intakes by
WHO and the Food and Agriculture Organization of the United Nations (FAO) [27,28]. Zinc
tablets were provided as water-dispersible tablets produced by Nutriset SAS (Malaunay,
France) containing 5 mg zinc or an identical placebo. The caregivers were advised to provide
the tablet once daily, dissolved in water or breast milk, but not with other foods. SQ-LNS and
packages of tablets were labeled with one of eight color codes (two colors per intervention
group). Caregivers were given brief feeding advice at enrollment, which included the above-de-
scribed instructions for SQ-LNS and tablets and recommendations to continue breastfeeding
and to provide a variety of nutritious foods.
Procedures
At the time of enrollment, children’s length, weight, mid-upper arm circumference (MUAC)
and head circumference (HC) were measured in IC and NIC. Maternal height and weight, and
information on the child’s dietary practices and family socio-economic status (SES) were also
obtained for all children. The age of the participants was confirmed from health cards. A capil-
lary sample was collected for onsite analyses of Hb concentration (Hemocue 201+, HemoCue
AB, Ängelholm, Sweden) and a rapid diagnostic test (RDT) for malaria parasites, based on his-
tidine-rich protein II (SD BIOLINE Malaria Ag P.F/Pan, Standard Diagnostics, INC., Kyonggi-
do, Korea). Capillary blood (300 μL) was collected in microcuvettes containing lithium heparin
(CB 300 LH, Sarstedt AG & Co, Nümbrecht, Germany) for assessment of zinc protoporphyrin
(ZPP) concentration. In case of illness, all children screened received free medical treatment(s):
in case of diarrhea oral rehydration salts (ORS) packets were provided, children with fever re-
ceived paracetamol and children with a positive RDT received anti-malarial treatment (artesu-
nate-amodiaquine combination therapy and paracetamol). Children with Hb<80 g/L received
anthelmintic treatment (mebendazole 200 mg/day for 3 days) and iron supplements (2–6 mg
iron/kg body weight for 30 days). Children with weight-for-length<70% of the median of the
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NCHS/WHO growth reference [24] or with malaria or diarrhea with complications or any
other illness requiring medical follow up were referred to the health center. Enrollment contin-
ued until the target sample size was met. In the case of twins, both were enrolled in the study,
but only one was randomly selected for inclusion in the data analysis.
Children in the IC were visited weekly for delivery of intervention products and morbidity
surveillance using standardized data collection tools. During each visit, reported LNS and tablet
consumption was recorded, and empty and unused packages were collected for assessment of
adherence. At each visit, the field worker evaluated the child for the presence of clinical danger
signs, and evidence of uncomplicated diarrhea, fever, or malaria, which were treated in the
community, as described above. In case of reported fever on the day of or the day before the
Table 1. Nutrients provided in 20 g SQ-LNS for infants and young children, in comparison toWorld Health Organization/Food and Agriculture Or-
ganization (WHO/FAO) Recommended Nutrient Intakes (RNI) [27].
Nutrient Unit SQ-LNS WHO/FAO RNI
7–12 months 1–3 yrs
Energy kcal 118 - -
Protein g 2.6 10.5 11.9
Fat g 9.6 40–60% energy1
Linoleic acid G 4.46 3.0–4.5% energy
α-Linolenic acid G 0.58 0.4–0.6% energy
Vitamin A Μg 400 400 400
Thiamin (B1) Mg 0.3 0.3 0.5
Riboﬂavin (B2) Mg 0.4 0.4 0.5
Niacin (B3) Mg 4 4 6
Pantothenic acid (B5) Mg 1.8 1.8 2
Vitamin B6 Mg 0.3 0.3 0.5
Vitamin B12 Μg 0.5 0.7 0.9
Folic acid Μg 80 80 150
Vitamin C Mg 30 30 30
Vitamin D Μg 5 5 5
Vitamin E Mg 6 2.7 5
Vitamin K Μg 30 10 15
Calcium Mg 280 400 500
Copper Mg 0.34 - -
Iodine Μg 90 90 90
Iron Mg 6 18.62 11.62
Magnesium Mg 40 54 60
Manganese Mg 1.2 - -
Phosphorus Mg 190 - -
Potassium Mg 200 - -
Selenium μg 20 10 17
Zinc mg 0, 5 or 103 8.44 8.34
1 Acceptable macronutrient distribution range recommended to reduce gradually from 40–60% at 6 months to 35% at 24 months and to 25–35% for 2
years and older [28].
2 RNI for an assumed bioavailability of 5%.
3 Zinc content depending on intervention group.
4 RNI for low bioavailability.
doi:10.1371/journal.pone.0122242.t001
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surveillance visit, the field worker performed an RDT and measured aural body temperature.
Children with danger signs, and diarrhea, fever and malaria with complications and any other
cases of severe illness were referred to the health center for evaluation and treatment. Surveil-
lance field workers participated in regular training, and refresher sessions and were overseen
by field supervisors and two study physicians. A randomly selected sub-sample of children par-
ticipated in 12-hr home observations at 11 and 16 months of age, as described in more detail
elsewhere [29].
The anthropometric measurements described above were repeated at 12 and 15 months in
IC only. From the age of 9 to 18 months, children in NIC were not supplemented nor visited
by study personnel; they relied on standard care provided by the family and health system. At
18 months, all children (IC and NIC) were invited for a final follow up examination, where an-
thropometric assessments were repeated, and Hb concentration was assessed. Children’s and
mothers’ weights were measured to 50 g precision (Seca Model 383 and Seca Model 874) and
children’s length (Seca Model 417), MUAC (26 cm Tri-Colored Single-Slotted Insertion Tape),
HC (ShorrTape Measuring Tape), and mothers’ height (Seca Model 217) were measured to 0.1
cm precision. Four teams of two anthropometrists each completed measurements in both IC
and NIC and were systematically restandardized. During 12 standardization sessions, the mean
technical error of measurement (TEM) for length was 0.50 cm and ranged from 0.09 to 0.74
cm (N = 120) considering both intra- and inter-observer variability [30].
At enrollment, a subset of children in IC and NIC were randomly assigned to the “biochem-
istry sub-group” for a venous blood draw. To avoid intra-concession correlation in this sub-
group, only one child was randomly selected per family compound. Final venous blood sam-
ples were obtained from the same sub-set of children at 18 months of age. On both occasions,
children were free of symptoms of diarrhea and fever during the previous 48 hr, and 5 mL of
blood was drawn 1–2 hr after the last breastfeeding episode from an antecubital or dorsal meta-
carpal vein. Blood was collected in evacuated, trace element-free polyethylene tubes containing
lithium heparin (Sarstedt AG & Co, Nümbrecht, Germany), stored on ice and transported to
the field laboratory, where ZPP was assessed in unwashed capillary whole blood by hemato-
fluorometer (206D, AVIV Biomedical Inc., Lakewood, NJ, USA). Plasma was separated from
heparinized venous blood by centrifuging at 2800 rpm for 10 min and stored at -20°C until
shipped on dry ice to the respective laboratories for analysis. All blood collection and process-
ing procedures conformed with recommendations by the International Zinc Nutrition Consul-
tative Group (IZiNCG) [31]. pZn was determined by inductively-coupled plasma atomic
emission spectrometry following overnight digestion in 70% nitric acid at the Children’s Hos-
pital Oakland Research Institute [32,33]. C-reactive protein (CRP) and α-1-acid glycoprotein
(AGP) were analyzed by ELISA by DBS-Tech in Willstaett, Germany [34].
Outcomes
Length-for age (LAZ), weight-for-age (WAZ), and weight-for-length z-scores (WLZ) were cal-
culated according to the World Health Organization 2006 growth standards [35]. Stunting,
underweight and wasting were defined as<-2 standard deviation (SD) LAZ, WAZ andWLZ,
respectively. Diarrhea was defined as the presence of3 loose or liquid stools per 24 hr. Re-
ported fever was defined as any fever reported by the caregiver. Confirmed fever was defined as
aural temperature>37.5°C. Any episode of reported or confirmed fever associated with a
positive RDT was defined as malaria. A child was considered at risk for malaria if the child
did not receive any antimalarial treatment within the previous 21 days. New episodes of diar-
rhea and fever were considered when at least 48 hr had elapsed since a previous episode. To
assess food security, the Household Food Insecurity Access Scale (HFIAS [36]) was adjusted
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for season and year. Using principal components analysis, an asset index was computed from
information on baseline ownership of a set of assets, lighting source, drinking water supply,
sanitation facilities, and flooring materials [37]. pZn and ZPP concentrations were adjusted
for the presence of inflammation (elevated acute phase proteins categorically defined as
CRP>5 mg/L, AGP>1 g/L, or both). Cut-offs used to define deficiency for each indicator
were: pZn< 65 μg/dL; Hb< 110 g/L; ZPP>70 μmol/mol heme.
Statistical Analyses
The primary outcomes were growth, incidence of diarrhea, incidence of malaria and pZn. All
statistical analyses were completed with SAS System software for Windows release 9.2 (SAS In-
stitute, Cary, North Carolina, USA). Data are presented as means ± SD, unless otherwise
noted. Treatment groups remained masked until all statistical analyses were completed and
main conclusions were drawn.
Descriptive statistics were used to examine all variables. Because the method of allocating
communities to the two cohorts did not result in equal probabilities of being selected for
intervention, selected variables were compared between cohorts using linear mixed models
for continuous variables, mixed logistic regression models for binary variables, including ran-
dom effects of village and concession, and Chi-square tests accounting for community for non-
binary categorical variables. Covariates and potential effect modifiers were defined prior to
analyses. Linear mixed model ANCOVA (SAS MIXED procedure) was used to compare an-
thropometric outcomes, and Hb, pZn, AGP and CRP concentrations between the two cohorts,
among the four intervention groups and among the five groups (four intervention groups and
NIC) with adjustment for baseline value, age, other relevant variables and random effects (vil-
lage, concession, if appropriate). Differences in the prevalence of stunting, underweight, and
wasting at the end of the study were compared with mixed model logistic regression (SAS
GLIMMIX procedure) adjusting for respective baseline z-score and other co-variates. Potential
modifying effects with an interaction with the treatment group and/or cohort were considered
significant if P<0.1. The modifying effects of baseline LAZ on the change in LAZ was exam-
ined by estimating adjusted means at the 10th, 50th and 90th percentile of baseline LAZ.
Morbidity outcomes were compared by using mixed effects logistic regression (SAS
GLIMMIX procedure), including random effects of concession, and accounting for overdisper-
sion. Treatment of diarrhea included treatments provided both by project field workers and
health centers. For treatment of malaria, only the treatment provided by field workers was con-
sidered. Differences in mortality rates between enrollment and end of the study were compared
with logistic regression including random effects of village and concession.
Results
Of 3402 children screened for eligibility, 3220 were enrolled in the study (Fig. 1). Of these,
2435 were randomly assigned to one of the 4 treatment groups in the IC and 785 to the NIC.
Among the four intervention groups, 19.5% dropped out by the final visit at 18 months. In the
NIC, 15.2% were lost to anthropometric follow up at 18 months. Caregivers of 97.1% of chil-
dren in the intervention groups provided morbidity surveillance information for at least 30
days and 78% provided information for at least 35 weeks, with no difference in participation
rates among the four intervention groups.
Potential biases associated with loss to follow up were assessed. There were no differences in
child, maternal, or household characteristics or SES between children who completed the study
and those who dropped out, except for maternal age. Mothers of children who completed the
study were slightly older than those of non-completers (27.0 ± 6.7 vs. 26.2 ± 6.7; P = 0.004).
SQ-LNS along with Illness Treatment Reduces Stunting in Young Children
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Fig 1. Flow diagram of clusters and participant progression through the iLiNS-ZINC trial.
doi:10.1371/journal.pone.0122242.g001
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At enrollment, children had a mean age of 9.4 ± 0.35 months, and almost all children
(99.9%) were still breastfed. Most baseline child and maternal characteristics did not differ
among the groups (Table 2). However, WAZ and WLZ of children in LNS-Zn10 were signifi-
cantly lower than in children in the LNS-TabZn5 group at baseline. There was also a significant
difference in maternal education and marital status/rank. More women in NIC had no educa-
tion (67.6%) compared to women in the 4 intervention groups (56.2–60.8%). Although other
Table 2. Child andmaternal baseline characteristics by group.
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5 NIC P-
value1
N 602 613 603 617 785
Child characteristics
Age (months) 2 9.4 ± 0.35 9.4 ± 0.35 9.4 ± 0.35 9.4 ± 0.36 9.4 ± 0.35 0.447
Male 305 (51) 299 (49) 320 (53) 304 (49) 392 (50) 0.600
Hemoglobin (g/L) 90 ± 15 90 ± 16 89 ± 15 90 ± 15 89 ± 16 0.747
Adjusted ZPP3 (μmol/mol heme) 168.1 (161.1,
175.5)
175.0 (168.0,
182.2)
172.2 (165.0,
179.7)
179.1 (171.6,
186.8)
168.8 (1622,
175.7)
0.293
Positive RDT4 369 (61) 358 (58) 368 (61) 351 (57) 532 (68) 0.244
Still breastfed 600 (100) 612 (99.8) 603 (100) 617 (100) 784 (99.9) 1.000
Maternal characteristics
Maternal age (yrs) 26.6 ± 6.5 27.2 ± 6.7 26.9 ± 6.8 26.9 ± 7.1 26.8 + 6.5 0.669
Maternal height (cm) 162.3 ± 5.9 162.3 ± 5.7 161.7 ± 5.5 162.0 ± 5.6 162.5 ± 5.8 0.195
Maternal weight (kg) 55.1 ± 7.8 55.3 ± 7.4 54.8 + 7.8 55.3 ± 8.2 54.5 ± 7.5 0.797
Maternal BMI (kg/m2) 20.9 ± 2.5 21.0 ± 2.4 20.9 ± 2.6 21.0 ± 2.6 20.6 ± 2.4 0.925
< 18.5 80 (13.3) 76 (12.4) 90 (15.0) 83 (13.5) 125 (15.9) 0.209
18.5–25 487 (80.9) 505 (82.5) 471 (78.4) 488 (79.1) 624 (79.5)
> 25 35 (5.8) 31 (5.1) 40 (6.7) 46 (7.4) 36 (4.6)
Maternal education <0.0001
No education 359 (60.8) 342 (56.2) 337 (56.3) 353 (57.7) 528 (67.6)
Informal education 179 (30.3) 205 (33.7) 194 (32.4) 182 (29.7) 167 (21.4)
1 year of formal education 52 (8.8) 61 (10.0) 67 (11.2) 77 (12.6) 86 (11.0)
Marital status/rank 0.005
Single, divorced, widowed 11 (1.9) 19 (3.1) 13 (2.2) 15 (2.4) 18 (2.3)
Sole wife 333 (56.4) 294 (48.5) 333 (55.9) 363 (59.3) 390 (49.9)
1st wife in polygamous
household
91 (15.4) 96 (15.8) 99 (16.6) 83 (13.6) 149 (19.1)
2nd wife in polygamous
household
155 (26.3) 197 (32.5) 151 (25.3) 151 (24.7) 224 (28.7)
Adjusted HFIAS5 2.96 (2.62, 3.30) 2.61 (2.32, 2.91) 2.98 (2.64, 3.33) 2.62 (2.33, 2.92) 3.11 (2.81, 3.42) 0.354
Asset index 0.10 (0.01, 0.18) 0.15 (0.06, 0.24) 0.04 (-0.04, 0.12) 0.16 (0.07, 0.24) -0.34 (-0.42, -0.27) 0.288
HFIAS, Household food insecurity access scale; LAZ, length-for-age z-score; positive RDT, positive result of a HRP-II (histidine-rich protein II) rapid
diagnostic test for malaria parasites; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score; ZPP, zinc protoporphyrin
1P-values are for Chi square tests from survey procedure for comparing proportions in more than 2 categorical variables across groups or logistic
regression for categorical variables, and linear mixed model for continuous variables. All comparison were done adjusting for cluster randomization
(village, concession);
2Mean ± SD, geometric mean (95% CI) and n (%), all such values.
3ZPP adjusted categorically for RDT result;
4Malaria is deﬁned as a positive result of a HRP-II rapid diagnostic test for malaria parasites
5Household food insecurity access scale (HFIAS) adjusted for season.
doi:10.1371/journal.pone.0122242.t002
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SES characteristics were not significantly different between groups, there was a tendency to-
wards lower SES in the NIC.
Caregivers reported high daily adherence to SQ-LNS (96.8% ± 6.5%) and to tablets (97.4% ±
6.4%). Disappearance rates of both products also indicated high weekly adherence [29]. In con-
trast, during the 12-hr home observations only 62.6% and 54.1% of children at 11 and
16-months, respectively, were observed receiving SQ-LNS during the 12-hr observation peri-
ods and 32.0% and 27.1%, respectively, were observed receiving tablets.
Mean baseline Hb was 89 ± 15 g/L, and 91.1% of the children were anemic at enrollment. At
18 months of age, mean Hb concentration increased significantly in IC compared to NIC, with
no difference among the four intervention groups (Table 3). This increase in Hb concentration
resulted in a final anemia prevalence of 79.1% in IC, compared with 91.1% of children in NIC
(P<0.0001). Mean baseline pZn was 69.0 ± 1.2 μg/dL and 35.2% of children had low pZn con-
centration at enrollment. There was no difference in final mean pZn among any of the study
Table 3. Hemoglobin, plasma zinc concentration and indicators of inflammation in children at 9 and 18 months1.
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5 P-value among 4
intervention groups
IC NIC P-value
between
cohorts
Hemoglobin2
N at 9 mo 602 613 603 617 2435 785
Hb at 9 mo (g/L) 89 ± 15 90 ± 16 89 ± 15 90 ± 15 0.735 89 ± 15 88 ± 16 0.417
N at 18 mo 489 498 489 481 1960 664
Hb at 18 mo (g/L) 97 ± 15 97 ± 15 98 ± 15 98 ± 15 0.613 97 ± 15a 88 ± 16b <0.0001
Anemic (Hb <110 g/L) at
18 mo (%)
392 (80.2) 390 (78.3) 384 (78.5) 383 (79.6) 0.848 1549
(79.1)b
605 (91.1)a <0.0001
Adjusted plasma zinc concentration3,4
N at 9 and 18 mo 84 74 79 73 310 93
pZn at 9 mo (μg/dL) 68.1 ± 1.21 68.1 ± 1.18 71.0 ± 1.16 71.3 ± 1.21 0.212 69.6 ± 1.19 67.0 ± 1.22 0.090
pZn at 18 mo (μg/dL) 63.5 ± 1.21 64.6 ± 1.18 64.9 ± 1.19 64.8 ± 1.15 0.742 64.4 ± 1.18 64.7 ± 1.18 0.831
Low zinc status
(pZn < 65 μg/dL) at 18
mo (%)
50 (59.5) 42 (56.8) 43 (54.4) 34 (46.6) 0.723 169 (54.5) 51 (54.8) 0.425
C-reactive protein3
N at 9 and 18 mo 84 75 79 73 311 93
CRP at 9 mo (mg/L) 1.94 ± 6.49 3.42 ± 5.35 2.59 ± 5.86 2.97 ± 6.34 0.225 2.65 ± 6.04 2.40 ± 5.87 0.605
CRP at 18 mo (mg/L) 2.64 ± 5.31 2.85 ± 4.83 2.20 ± 4.73 2.12 ± 4.65 0.580 2.44 ± 4.88 3.12 ± 5.50 0.175
Elevated CRP (CRP 5
mg/L) at 18 mo (%)
23 (27.4) 27 (36.0) 23 (29.1) 17 (23.3) 0.442 90 (28.9)b 39 (41.9)a 0.010
α-1-acid glycoprotein3
N at 9 and 18 mo 84 75 79 73 311 93
AGP at 9 mo (g/L) 1.08 ± 1.27 1.09 ± 1.27 1.08 ± 1.25 1.05 ± 1.33 0.863 1.08 ± 1.28 1.05 ± 1.28 0.325
AGP at 18 mo (g/L) 1.08 ± 1.39 1.07 ± 1.45 1.07 ± 1.41 1.03 ± 1.35 0.880 1.06 ± 1.40 1.11 ± 1.45 0.308
Elevated AGP (AGP
1.0 g/L) at 18 mo (%)
49 (58.3) 45 (60.0) 48 (60.8) 41 (56.2) 0.967 183 (58.8) 55 (59.1) 0.829
AGP, α-1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin; IC, intervention cohort; mo, months; NIC, non-intervention cohort; pZn, plasma
zinc concentration
1 Adjusted mean ± SD, and n (%); all such values. Values in the same row with different superscript letters are signiﬁcantly different (P<0.05).
2 Mean adjusted for cluster randomization (village, concession) and baseline value.
3 Venous blood samples collected in a randomly selected sub-group only. Mean adjusted for cluster randomization (village) and baseline value.
4 pZn also adjusted for time of blood draw, time since last breastfeeding episode and categorically adjusted for CRP and AGP concentration
doi:10.1371/journal.pone.0122242.t003
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groups nor between IC and NIC. The intervention also did not have a significant impact on
mean AGP and CRP concentrations at 18 months, nor on the prevalence of elevated AGP.
However, significantly fewer IC children had elevated CRP at 18 months than NIC children
(28.9% vs. 41.9%; P = 0.010).
At 18 months, adjusted mean length, weight, MUAC and HC were all significantly greater
in IC children compared to NIC children (Table 4), but there were no differences among the 4
intervention groups in any of these outcomes. There was a significant modifying effect of initial
length on the difference in growth between IC and NIC children (P = 0.023; Fig. 2). In particu-
lar, the change in length was significantly greater among IC children with the lowest 10th per-
centile of initial length compared to NIC children (P<0.0001). At baseline, mean LAZ, WAZ
Table 4. Anthropometry at baseline and after 9 mo of intervention in young Burkinabe children.
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5 P-value among
4 groups2
IC NIC P-value
between
cohorts2
N 602 613 603 617 2435 785
Length at 9 mo
(cm)1
68.7 ± 2.6 68.7 ± 2.6 68.5 ± 2.6 68.9 ± 2.7 0.138 68.7 ± 2.6 68.9 ±2.7 0.393
Length at 18 mo
(cm)
77.7 ± 3.0 77.7 ± 3.0 77.7 ± 3.1 77.8 ± 2.9 0.962 77.7 ± 3.0a 77.0 ± 3.4b < 0.0001
Weight at 9 mo (kg) 7.41 ± 0.95ab 7.41 ± 1.03ab 7.30 ± 0.95b 7.49 ± 1.03a 0.013 7.40 ± 0.99 7.44 ± 1.04 0.625
Weight at 18 mo
(kg)
9.31 ± 1.00 9.30 ± 1.09 9.29 ± 1.11 9.33 ± 1.05 0. 784 9.31 ± 1.07 a 9.02 ± 1.18b < 0.0001
MUAC at 9 mo
(cm)
13.3 ± 1.1ab 13.3 ± 1.2ab 13.2 ±1.1b 13.4 ± 1.2a 0.002 13.3 ± 1.1 13.3 ± 1.2 0.684
MUAC at 18 mo
(cm)
13.8 ± 1.0 13.8 ± 1.0 13.8 ± 1.1 13.8 ± 0.99 0.553 13.8 ± 1.0a 13.5 ± 1.1b < 0.0001
HC at 9 mo (cm) 42.6 ± 1.4 42.6 ± 1.4 42.6 ± 1.3 42.7 ± 1.3 0.789 42.6 ± 1.4 42.6 ± 1.3 0.330
HC at 18 mo (cm) 44.6 ± 1.4 44.6 ± 1.4 44.6 ± 1.3 44.6 ± 1.3 0.983 44.6 ± 1.3a 44.4 ± 1.3b < 0.0001
LAZ at 9 mo -1.22 ± 1.07ab -1.21 ± 1.11ab -1.33 ± 1.07b -1.14 ± 1.10a 0.029 -1.23 ± 1.09 -1.19 ± 1.13 0.631
LAZ at 18 mo -1.44 ± 1.05 -1.45 ± 1.09 -1.45 ± 1.10 -1.43 ± 1.00 0.968 -1.44 ± 1.06a -1.74 ± 1.17b < 0.0001
WAZ at 9 mo -1.42 ± 1.10ab -1.41 ± 1.16ab -1.58 ± 1.08b -1.34 ± 1.16a 0.003 -1.44 ± 1.13 -1.42 ± 1.19 0.834
WAZ at 18 mo -1.22 ± 0.94 -1.24 ± 1.00 -1.24 ± 1.04 -1.20 ± 0.94 0.721 -1.23 ± 0.98a -1.51 ± 1.12b < 0.0001
WLZ at 9 mo -0.99 ± 1.06ab -0.98 ± 1.08ab -1.11 ± 0.99b -0.91 ± 1.06a 0.015 -1.00 ± 1.05 -1.01 ± 1.06 0.801
WLZ at 18 mo -0.72 ± 0.89 -0.74 ± 0.94 -0.77 ± 1.00 -0.70 ± 0.89 0.472 -0.73 ± 0.93a -0.93 ± 1.01b < 0.0001
Stunting at 9 mo, n
(%)
139 (23.1) 135 (22.1) 158 (26.2) 124 (20.2) 0.138 556 (22.9) 164 (20.9) 0.318
Stunting at 18 mo,
n (%)
146 (29.9) 149 (30.1) 161 (32.8) 117 (24.4) 0.536 573 (29.3) b 261 (39.3)a <0.0001
Underweight at 9
mo, n (%)
159 (26.5)b 180 (29.4)ab 205 (34.0)a 163 (26.4)ab 0.015 707 (29.0) 244 (31.1) 0.560
Underweight at 18
mo, n (%)
91 (18.6) 102 (20.4) 129 (26.3) 73 (15.2) 0.051 395 (20.1)b 206 (30.9)a 0.0001
Wasting at 9 mo, n
(%)
100 (16.6) 94 (15.4) 111 (18.4) 88 (14.3) 0.261 393 (16.2) 136 (17.3) 0.674
Wasting at 18 mo,
n (%)
35 (7.2)b 44 (8.9)ab 65 (13.2)a 26 (5.4)b 0.003 170 (8.7) b 90 (13.5)a 0.0003
HC, head circumference; LAZ, length-for-age z-score; mo, months; MUAC, mid-upper arm circumference; WAZ, weight-for-age z-score; WLZ, weight-for-
length z-score
1 Adjusted mean ± SD and n (%), all such values. Values in the same row with different superscript letters are signiﬁcantly different (P<0.05).
2 Adjusting for cluster randomization (village, concession), baseline value, age and potential co-variates, when applicable.
doi:10.1371/journal.pone.0122242.t004
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andWLZ were -1.21 ± 1.10, -1.42 ± 1.14, and -0.99 ± 1.05, respectively, in all five groups com-
bined. These z-scores were significantly greater in IC children compared to NIC at 18 months,
with no difference among the 4 intervention groups. The increase in length and weight in IC
from 9 to 18 months resulted in a significantly lower prevalence of stunting, underweight and
wasting in IC compared to NIC. At 18 months, 39.3% of NIC children were stunted compared
to 29.3% of IC children (P<0.0001) and 13.5% of NIC children were wasted compared to 8.7%
of IC children (P = 0.0003). The prevalence of stunting did not differ among the four interven-
tion groups. However, the prevalence of underweight was marginally higher in children in the
LNS-Zn10 group compared to children in the LNS-TabZn5 group (26.3% vs 15.2%, P = 0.089).
Similarly, the prevalence of wasting in LNS-Zn10 (13.2%) was significantly higher than in
LNS-TabZn5 (5.4%) and LNS-Zn0 (7.2%; P = 0.003). In the 5-group comparison of wasting
prevalence, there was no difference between LNS-Zn10, LNS-Zn5 and NIC (P>0.05).
During the 9 months intervention period in the IC, the mean (95% confidence interval
(CI)) prevalence of diarrhea in all four groups combined was 3.08% (2.94, 3.22) and the mean
(± SD) diarrhea incidence was 1.10 ± 1.03 per 100 child-days. These did not differ among the
four intervention groups (Table 5). The intra-cluster (i.e., concession) correlation for diarrhea
incidence was ~0.16, resulting in a design effect of about 1.10 for diarrhea incidence. The pro-
portion of all diarrhea episodes treated according to the study protocol ranged from 36.4% to
41.3% and did not differ by study group. At enrollment, the proportion of children with a posi-
tive RDT (61.4% overall) did not differ among groups. During the 9 months follow up, the
overall mean malaria prevalence and mean malaria incidence did not differ by group. Almost
all malaria episodes were treated (99.0%), and treatment rates did not differ by study group.
Fig 2. Change in length by initial length in young children in Burkina Faso.
doi:10.1371/journal.pone.0122242.g002
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There were no significant differences in hospitalization (P = 0.394) or mortality (P = 0.125)
rates among children in the four intervention groups. At 18 months, caregivers were asked
whether they sought medical services for the study children, and retrospective reports were
marginally higher in IC versus NIC (57% vs 54%, P = 0.083), but did not differ among all five
study groups (P = 0.412). The mortality rate was significantly lower in IC than NIC (1.4% vs
3.2% P = 0.005). When all five study groups were compared, this difference was only significant
between NIC and LNS-Zn5 (Fig. 1).
Discussion
Provision of SQ-LNS along with simple feeding advice and treatment of confirmed cases of ma-
laria and reported diarrhea resulted in significantly greater growth velocity and lower preva-
lence of stunting, wasting and anemia among children in the IC compared to children in the
NIC. The growth effect was significantly greater among children whose initial length was
below the 10th percentile of initial length of study participants, indicating that those with the
greatest degree of initial growth restriction benefitted most. This reduction in stunting preva-
lence is of public health significance considering that stunting is associated with increased risk
of morbidity and mortality, impaired cognition and educational performance, lower adult
wages, and, when accompanied by excessive weight gain later in childhood, increased risk of
nutrition-related chronic diseases [1,2].
Within the IC, there were no detectable differences in zinc-related outcomes, such as in-
creased growth, morbidity reduction or change in pZn, regardless of the amount or form of
supplemental zinc, implying that the different amounts of zinc provided in SQ-LNS or as dis-
persible tablet were neither protective nor harmful. Possible explanations for these findings are
poor adherence to supplements, poor absorption of zinc from these supplements, deficiencies
Table 5. Prevalence and incidence of diarrhea andmalaria among young Burkinabe children receiving SQ-LNS and tablets from 9 to 18months of
age.
LNS-Zn0 LNS-Zn5 LNS-Zn10 LNS-TabZn5 P-value6
N 579 593 593 599
Prevalence (%)1
Diarrhea2 3.20 (2.93, 3.47) 3.14 (2.84, 3.44) 2.97 (2.70, 3.24) 3.01 (2.73, 3.29) 0.403
Malaria3 1.56 (1.44, 1.69) 1.67 (1.51, 1.83) 1.59 (1.45, 1.73) 1.61 (1.47, 1.76) 0.754
Incidence (per 100 child-days)1
Diarrhea 1.11 ± 1.05 1.14 ± 1.05 1.06 ± 0.98 1.08 ± 1.02 0.589
Treated diarrhea 0.41 ± 0.48 0.41 ± 0.54 0.41 ± 0.51 0.38 ± 0.52 0.711
% of diarrhea episodes treated4 39.7 36.4 41.3 37.6 0.330
Malaria 0.55 ± 0.49 0.55 ± 0.52 0.54 ± 0.48 0.52 ± 0.49 0.877
Treated malaria 0.55 ± 0.49 0.54 ± 0.52 0.53 ± 0.48 0.52 ± 0.48 0.813
% of malaria episodes treated5 99.2 99.1 99.4 98.3 0.518
1Prevalence shown as mean percent (95% CI) and incidence as mean ± SD per 100 child-days. Means are weighted for number of days of observation
for prevalence and number of days at risk for incidence.
2Diarrhea deﬁned as 3 liquid or semi-liquid stools reported by caregiver
3Malaria was deﬁned by a positive result of a HRP-II (histidine-rich protein II) rapid diagnostic test for malaria parasites
4Treatment of diarrhea included treatments provided by project ﬁeld workers and health centers
5 Treatment of malaria was considered if provided by project ﬁeld workers
6 P-values obtained from binominal regression models, which included a random effect of concession, baseline characteristics and potential covariates
and accounted for overdispersion.
doi:10.1371/journal.pone.0122242.t005
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of other nutrients causing limited responses, or lack of zinc deficiency in the study population.
Although reported adherence was very high, 12-hr home observations during home visits re-
vealed that only 59% of children were offered SQ-LNS, and only 30% of the children received a
tablet during the 12-hr home observation. Moreover, almost half of all children (46%) who
were offered a tablet on the day of observation received the tablet less than 30 min after a meal
[29]. Thus, it is possible that adherence to the zinc tablets and/or absorption of zinc from the
tablets were less than optimal. It is less likely that concurrent deficiencies of other nutrients
limited responses since SQ-LNS provided all IC children with 21 micronutrients and essential
fatty acids [11]. Absence of zinc deficiency in the study population is also an unlikely explana-
tion since 54% of children had low pZn at the end of the study.
Although there were no significant differences in meanWLZ among the four intervention
groups at the end of the study, the wasting prevalence at 18 months was significantly higher in
LNS-Zn10 (13.2%) compared to LNS-Zn0 (7.2%) and LNS-TabZn5 (5.4%; P = 0.003). It is un-
likely that this higher wasting prevalence in the LNS-Zn10 group was due to an adverse effect
of zinc. A meta-analysis of 22 studies of preventive zinc supplementation provided either as
tablets or syrup, including 13 studies that provided 10 mg supplemental zinc, found a small,
marginally significant, positive effect of zinc on change in weight-for-height z-score [6]. A pre-
vious study found no differences in LNS acceptability or LNS consumption in relation to zinc
content [26], so differences in LNS consumption is also an unlikely explanation. Rather, it
seems that the difference in final wasting prevalence is a chance finding given that we found no
other significant differences in any of the growth and morbidity outcomes among the interven-
tion groups.
While larger quantity LNS has proven useful in the treatment of children with severe acute
malnutrition [38], the potential of SQ-LNS to prevent malnutrition and improve health and
nutrition status is only beginning to be explored. In the present study, the standardized mean
difference of LAZ at the end of the study was 0.27 between the children in IC who received the
intervention package compared to children in NIC. Similarly, Adu-Afarwuah and colleagues
found a standardized mean difference of final LAZ of 0.26 between Ghanaian children who re-
ceived SQ-LNS compared to children in a non-intervention group, although the difference in
final LAZ at 12 months of age was not significant, probably due to the smaller sample size in
the Ghana study [14]. Over the 9-months intervention period we found an effect size in length
of 0.48. In contrast, a smaller but also significant effect size of 0.11 was found for the longitudi-
nal average monthly growth effect in Haiti [15]. Possible explanations for these differences are
the community-based provision of disease treatment and/or differences in initial LAZ of these
study populations. Whereas treatment of diarrhea and malaria was provided by the field team
in the present study, no treatment was provided in the studies in Ghana and Haiti. In addition,
the mean baseline LAZ was much lower in the Burkinabe children (-1.21 ± 1.10) compared to
the baseline LAZ of -0.20 ± 1.0 and -0.39 ± 1.20 in the studies in Ghana and Haiti, respectively.
A fourth trial in young Malawian children with mean initial LAZ of -1.00 ± 0.77 found that in-
fants with baseline LAZ below the median who received 50 g LNS gained more length than
children who received a micronutrient-fortified maize-soy flour for 12 months [13]. This is
consistent with our findings that children with the greatest degree of growth restriction
benefitted most.
Diarrhea is associated with a small decrease in linear growth over the long term [39], but
findings from longitudinal studies investigating the impact of malaria on growth are inconsis-
tent [40–43]. One study found that only Plasmodium vivax was a predictor of stunting and
wasting and not Plasmodium falciparum [44]; the latter was the most common parasite type in
our study. Because all children in the intervention groups received SQ-LNS along with simple
feeding advice and illness treatment, it is uncertain what proportion of the growth impact in IC
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children can be attributed to SQ-LNS alone and how much was due to the malaria and/or diar-
rhea treatment. In the present study, the frequency of treated malaria episodes did not have an
impact on average change in growth [45], and it is unlikely that the provision of ORS would
have an impact on growth. Nevertheless, to explore the possible effects of illness treatment we
compared the results of the present study with the outcomes of another zinc trial in a neighbor-
ing health district. In the neighboring study, zinc supplementation was provided only as dis-
persible zinc tablets along with community-based treatment of malaria and diarrhea, following
the same treatment protocol. In that study, where no SQ-LNS was provided, zinc supplements
and illness treatment did not increase the growth of young children compared to a non-inter-
vention group [46], suggesting that SQ-LNS may have been the critical growth-promoting
component of the current intervention package. However, other differences in the study de-
signs prevent firm conclusions.
We found a significant reduction in anemia prevalence in the IC children. These findings
are consistent with the study of SQ-LNS in Ghana, which also found a significant reduction in
anemia prevalence in children receiving SQ-LNS from 6 to 12 months of age compared to a
non-intervention group [19]. Similarly, studies of MNP also consistently find a beneficial im-
pact on anemia prevalence [47]. However, 79% of all children in IC still had a Hb concentra-
tion<110 g/L at the end of the intervention, despite the daily provision of 6 mg iron, 400 μg
retinol and B-vitamins in SQ-LNS, along with treatment for malaria and diarrhea. Thus, addi-
tional interventions would be needed to reduce the high anemia burden in this population.
Strengths of the current study include the large sample size, high participation rates, and
regular training and rigorous supervision of field staff. All anthropometrists participated in
regular standardization sessions as recommended by WHO [48]. In addition, the present study
included multiple strategies to assess adherence to the study products [29] and blood collection
and plasma analyses followed procedures recommended by IZiNCG [31].
Several limitations in the present study also have to be considered. One limitation was the
cluster assignment to intervention and non-intervention communities. To compensate for the
cluster design, we enrolled a large number of communities (25 IC and 9 NIC villages) and in-
cluded a design effect of 1.5 in calculating the NIC sample size. Also, adherence to the different
study products could not be definitely ascertained despite the use of a variety of strategies to as-
sess adherence [29]. Another weakness of our study is related to the partially blind study de-
sign. While participants, field workers and investigators remained blinded to the intervention
groups in IC during data collection, data analyses and result interpretation, the comparisons
between IC and NIC could not be blinded. However, all final anthropometric indicators were
consistently greater in IC and the stunting prevalence of 22.4% at 9 months in all children and
39.3% at 18 months of age in NIC are comparable to the national stunting prevalence in the
same age range (25.1% in 9–11 months old children and 41.6% in children aged 18–23 months)
in 2010 [49]. Moreover, a similar study in a neighboring health district with weekly contact for
morbidity surveillance and product distribution did not find a difference in growth between
the intervention and non-intervention group [46]. Thus, it is unlikely that the Hawthorne ef-
fect could explain the observed growth impact. Despite these considerations, the inclusion of
the NIC in our trial strengthened the study design, as it allowed the comparison of the inter-
vention package to the current standard care in rural southwestern Burkina Faso.
Because the trial was implemented in a malaria-endemic area, SQ-LNS and feeding recom-
mendations for the iLiNS studies were designed to minimize possible risks of iron supplemen-
tation [11]. In particular, the daily iron dose was half the recommended dose for MNP [50],
and caregivers were advised to feed the daily ration in two separate servings to avoid consum-
ing a large bolus of iron at a single meal. Moreover, treatment was provided for diagnosed
cases of malaria and diarrhea. A recent trial of MNP conducted in Pakistan found an increase
SQ-LNS along with Illness Treatment Reduces Stunting in Young Children
PLOS ONE | DOI:10.1371/journal.pone.0122242 March 27, 2015 15 / 19
in reported diarrhea and chest in-drawing among 6 to 18 month old children who received
MNP compared to a non-supplemented control group, although there was no difference in the
rates of persistent diarrhea, fever, or hospitalizations [51]. Because we did not collect continu-
ous morbidity data in the NIC, so as not to interfere with current treatment practices, the pres-
ent trial does not allow such a direct comparison of morbidity rates between IC and NIC. In an
effort to assess potential risks of the intervention, we asked caregivers at the end of the study to
report retrospectively any medical care seeking at local health centers and regional hospitals
over the 9-months study period. These reports were marginally higher in the IC (57%) com-
pared to the NIC (54%; P = 0.083), which was likely due to the fact that children in IC were re-
ferred to the health center by the morbidity surveillance worker for any illness other than
uncomplicated diarrhea and malaria. At the same time, there was a significantly lower mortali-
ty rate in IC than NIC (1.4% vs 3.2%; P = 0.005). While our study was not powered to assess
hospitalization and mortality rates, these findings together imply that providing SQ-LNS as
prescribed in the current study, along with malaria and diarrhea treatment, was likely
not harmful.
In summary, there were no differences in growth and morbidity outcomes among the four
intervention groups. Thus, the optimal level of zinc to be added to SQ-LNS remains uncertain.
Nevertheless, the provision of SQ-LNS along with brief feeding advice and illness treatment of
diagnosed cases of malaria and diarrhea had a significant beneficial impact on stunting, wast-
ing and anemia reduction. While we are not able to distinguish the impact of SQ-LNS from
the impact of health services, provision of malaria and diarrhea treatment is unlikely the sole
reason for the beneficial impact on growth. The findings of the present study suggest that
provision of SQ-LNS is a promising strategy to reduce childhood stunting and wasting when
coupled with greater access to health care, especially among children at greatest risk of
stunting.
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